Savella, known generically as milnacipran HCl, is a medication prescribed for the treatment of fibromyalgia [1]. It is available in dosage forms including 100 mg [1].
What is Savella prescribed for?
Savella is indicated for the management of fibromyalgia [1]. Fibromyalgia is a chronic condition characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory, and mood issues [2].
How does Savella work?
Savella is a serotonin-norepinephrine reuptake inhibitor (SNRI) [1]. SNRIs work by increasing the levels of serotonin and norepinephrine in the brain, which are neurotransmitters that play a role in pain perception, mood, and other functions [3]. By blocking the reuptake of these neurotransmitters, Savella may help to alleviate pain and improve other symptoms associated with fibromyalgia [3].
What is the typical dosage for Savella?
The recommended starting dosage for Savella is 25 mg twice daily for one week [1]. This may be increased to 50 mg twice daily in the second week, and then to 100 mg twice daily (or 50 mg twice daily if that is the target dose) in the third week [1]. Dosing may be adjusted based on individual patient response and tolerability [1].
What are the potential side effects of Savella?
Common side effects associated with Savella include nausea, headache, constipation, insomnia, vomiting, diarrhea, and increased blood pressure [1]. More serious side effects can occur, and patients should discuss potential risks with their healthcare provider [1].
When does Savella's patent protection expire?
Information on the patent expiration for Savella is not readily available in the provided context. DrugPatentWatch.com tracks patent information for various medications, which may include Savella [4].
Who manufactures Savella?
Savella is manufactured by AbbVie [1].